Omalizumab antibody | AbD20760_hIgG1
A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human anti omalizumab, clone AbD20760_hIgG1 (HCA237P) at a concentration of 2 μg/ml followed by QuantaBlu™ fluorogenic peroxidase substrate
A microtiter plate was coated over night with various antigens. For IgE/drug complex antigen, human IgE (HCA171) was immobilized to the plate. After washing and blocking, omalizumab was added. After further incubation and washing steps, detection was performed using HRP-conjugated Human anti omalizumab,clone AbD20760_hIgG1 (HCA237P) titrated to the given concentrations in PBST, followed by QuantaBlu™ fluorogenic peroxidase substrate
A microtiter plate was coated over night with human IgE (HCA171) at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of omalizumab. Detection was performed using HRP-conjugated Human anti omalizumab, clone AbD20760_hIgG1 (HCA237P) at a concentration of 2 µg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate
Filter by Application:
E ResetHuman anti Omalizumab (Drug/Target Complex)
- Product Type
- Monoclonal Antibody
- Clone
- AbD20760_hIgG1
- Isotype
- IgG1
- Specificity
- Omalizumab
- Region
- DRUG/TARGET COMPLEX
Quick Links:
Antibody Quality and 
Unrivaled 
| Human anti omalizumab, clone AbD20760_hIgG1 binds specifically to the omalizumab/IgE (drug/target) complex. The antibody does not recognize free omalizumab or free human IgE. It can be used in bioanalytical assays to detect bound omalizumab or biosimilar products exclusively. Clone AbD20760_hIgG1 can be used to develop a pharmacokinetic (PK) antigen capture assay to measure omalizumab captured via immobilized human IgE or to measure the level of drug/IgE complex in preclinical or clinical samples. This product is in a full immunoglobulin format and is available directly labeled with HRP. The antibody is also available in unlabeled Fab format (HCA238). Omalizumab (brand name Xolair®) is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody used in the treatment of patients with moderate or severe asthma who have demonstrated a positive allergy skin test and whose symptoms are not controlled by inhaled corticosteroids. Allergic asthma is mediated by IgE released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (FcεRI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of asthma. Omalizumab is directed against the Fc region of human immunoglobulin E (IgE). By binding to circulating IgE at the site of FcεRI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release. Treatment with omalizumab has also been demonstrated to reduce the expression of FcεRI on mast cells and basophils, providing additional clinical benefit. View a summary of all anti-omalizumab antibodies |
- Product Form
- Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line.This antibody is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Omalizumab/IgE complex
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD = 0.58 nM by real time, label free molecular interaction analysis on immobilized omalizumab in complex with human IgE.
- Approx. Protein Concentrations
- IgG concentration 0.5 mg/ml
- Regulatory
- For research purposes only
- Guarantee
- 12 months from date of despatch
- Acknowledgements
- This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Xolair®is a registered trademark of Novartis.
This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |  |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used in a direct ELISA to detect the omalizumab/IgE complex or to detect omalizumab bound to immobilized IgE.
Protocol: PK antigen capture ELISA to measure bound drug exclusively
| Description | Product Code | Applications | Pack Size | List Price | Your Price | Quantity | |
|---|---|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | Hispec Assay Diluent | ||||||
| Recombinant Human IgE Lambda | HCA171 | E | 0.1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Recombinant Human IgE Lambda | ||||||
| Recombinant Human IgE Kappa | HCA190 | E | 0.1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Recombinant Human IgE Kappa | ||||||
| Human anti Omalizumab | HCA235 | E | 0.1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Human anti Omalizumab | ||||||
| Human anti Omalizumab | HCA236 | E | 0.1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Human anti Omalizumab | ||||||
| Human anti Omalizumab (Drug/Target Complex) | HCA238 | E | 0.1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Human anti Omalizumab (Drug/Target Complex) | ||||||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | CJ | 3 Conjugations For 400µg Antibody | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | LYNX Rapid HRP Antibody Conjugation Kit | ||||||
References for Omalizumab antibody
-
Harth, S. et al. (2019) Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics.
MAbs. 11 (1): 178-190.
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
View more products with Omalizumab specificity
Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.
Yes, sign me up